Literature DB >> 19822050

Early inflammatory clinics. Experience with early arthritis/back pain clinics.

V Goëb1, J Smolen, P Emery, H Marzo-Ortega.   

Abstract

There is a clear need to assess patients presenting with a new onset of inflammatory peripheral arthritis and/or back pain early. Indeed, the clinical presentation of rheumatoid arthritis (RA) is not always characteristic but its early diagnosis is crucial to prevent irreversible structural damage. Likewise low back pain is common in the general population but may be related to ankylosing spondylitis (AS) and other axial spondyloarthritis (SpA) in up to 5% of cases. Mounting evidence suggests that early intervention leads to improve outcome both in RA and SpA which has important socioeconomic implications. Early inflammatory clinics (EIC) should therefore be considered in every rheumatology department to facilitate the early assessment and diagnosis of these patients allowing for prompt and targeted therapeutic intervention. In addition the EICs allow for a better focused follow-up of these patients in appropriate secondary clinics. Since the sustained remission of inflammatory and autoimmune diseases such as RA is highly dependent on how early treatment is instigated and its efficacy regularly assessed, there is legitimacy for the EICs. Furthermore, there is a clear research interest in building early inception cohorts that allow for the characterization of the different disease phenotypes.

Entities:  

Mesh:

Year:  2009        PMID: 19822050

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  2 in total

1.  Rheumatoid arthritis: Why wait? Explaining delays in seeking therapy for early arthritis.

Authors:  Fabiola Atzeni; Piercarlo Sarzi-Puttini
Journal:  Nat Rev Rheumatol       Date:  2012-03-06       Impact factor: 20.543

2.  Early arthritis clinic is effective for rheumatoid and psoriatic arthritides.

Authors:  M K Nisar
Journal:  Rheumatol Int       Date:  2019-02-19       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.